SCHEMBL17796563

SCHEMBL17796563

CO[C@H]1CCCN(c2ccc(N)nc2)C1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 1/20 0.50
LRRK2 Q5S007 3/20 0.42
PIK3CA P42336 2/20 0.42
MTOR P42345 2/20 0.42
FFAR2 O15552 1/20 0.41
IDH1 O75874 1/20 0.41
HRH3 Q9Y5N1 1/20 0.40
CHRNB2 P17787 4/20 0.38
CHRNA4 P43681 4/20 0.38
CHRNB4 P30926 2/20 0.38
CHRNA3 P32297 2/20 0.38
CDK4 P11802 1/20 0.38
TRPC6 Q9Y210 3/20 0.37
DGAT2 Q96PD7 1/20 0.37
ALOX5AP P20292 1/20 0.36
FEN1 P39748 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2792128 0.91 PIK3CA (0.49) MAP4K4PIK3CAMTORFFAR2IDH1
SCHEMBL14913101 0.86 CHRNB2 (0.42) PIK3CAMTORCHRNB2CHRNA4CHRNB4
SCHEMBL2822118 0.84 PIK3CA (0.53) MAP4K4PIK3CAMTORHRH3CHRNB2
SCHEMBL27881809 0.82 MAPT (0.49) MAP4K4FFAR2HRH3
SCHEMBL25065178 0.81 MAP4K4 (0.47) MAP4K4LRRK2CHRNB2CHRNA4
SCHEMBL23114676 0.81 MAP4K4 (0.52) MAP4K4LRRK2PIK3CAMTORIDH1
SCHEMBL23089590 0.80 HRH3 (0.42) PIK3CAMTORHRH3TRPC6DGAT2
SCHEMBL18779659 0.79 MAP4K4 (0.46) MAP4K4CHRNB2CHRNA4ALOX5APFEN1
SCHEMBL24747237 0.78 CHRNB2 (0.40) LRRK2PIK3CAMTORHRH3CHRNB2
SCHEMBL17796348 0.78 SMPD3 (0.47) LRRK2CHRNB2CHRNA4ALOX5APFEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160159773-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-09 US disclosed
US-20160159773-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-09 US disclosed
US-20160159773-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-09 US disclosed
EP-3029031-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-06-08 EP disclosed
EP-3029031-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160159773-A1 HETEROCYCLIC COMPOUND TYK2, SSB, UACA MAP4K4 262/4885LRRK2 369/4885PIK3CA 2494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.